AHR and cancer: Activation of AhR by KYN, a product of IDO1 and TDO2, prompts the generation of immune-tolerant dendritic cells (DCs) and regulatory T cells, which together shape a tumor immune microenvironment incapable of recognizing and destroying cancer cells (24).